About cassava sciences - SAVA
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.
SAVA At a Glance
Cassava Sciences, Inc.
6801 North Capital of Texas Highway
Austin, Texas 78731
| Phone | 1-512-501-2444 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -24,342,000.00 | |
| Sector | Health Technology | Employees | 30 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
SAVA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.781 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.124 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
SAVA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -811,400.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
SAVA Liquidity
| Current Ratio | 11.62 |
| Quick Ratio | 11.62 |
| Cash Ratio | 10.942 |
SAVA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -15.745 |
| Return on Equity | -17.192 |
| Return on Total Capital | -16.706 |
| Return on Invested Capital | -17.192 |
SAVA Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |
Cassava Sciences in the News
US opens criminal probe into pharma company over potential Alzheimer's drug fraud: report
A Texas-based pharmaceutical company is facing a criminal probe into allegations that it manipulated data in its studies on its Alzheimer's drug simuflam on Wednesday.